MARKET

NVO

NVO

Novo-Nordisk A/S
NYSE
123.45
-0.45
-0.36%
After Hours: 123.55 +0.1 +0.08% 19:49 04/16 EDT
OPEN
123.07
PREV CLOSE
123.90
HIGH
124.25
LOW
121.79
VOLUME
3.04M
TURNOVER
0
52 WEEK HIGH
138.28
52 WEEK LOW
74.66
MARKET CAP
550.80B
P/E (TTM)
44.79
1D
5D
1M
3M
1Y
5Y
LLY, VKTX, or NOVO: Which Weight-Loss Drugmaker Could Gain the Best Returns?
TipRanks · 3h ago
VGK Vs. QQQ: How Europe's 'GRANOLAS' Could Outperform The US 'Magnificent 7'
Europe's 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. The "Magnificent 7" stocks in the US lead returns and headlines in Europe. The Magnificent 7 is a proxy for the Invesco QQQ and Europe's FTSE Europe ETF "VGK" In the past year, the Mag 7 has outperformed Europe's GRanOLAS.
Seeking Alpha · 12h ago
Lexaria gets ethics board okay for oral GLP-1 study
Healthcare Lexaria gets ethics board okay for oral GLP-1 study. Lexaria Bioscience Corp. Said a third-party ethics review board has approved a human pilot study. The study will evaluate a pill formulation of the drug semaglutide.
Seeking Alpha · 13h ago
Buyback Bonanza: The Top 7 ETFs to Profit From Corporate Cash Splurges
80% of S&P 500 companies are entering pre-earnings buyback blackouts. Historically, corporate buybacks have bolstered stock prices. These buyback ETFs could be in an undervalued spot. IShares U.S. Dividend and BuybackETFs are seven to consider for April.
Investorplace · 17h ago
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health
NASDAQ · 21h ago
Eli Lilly's nationwide insulin pricing settlement called off
Eli Lilly's insulin pricing settlement called off. The settlement would have capped prices and provided $13.5 million to purchasers of Lilly's insulin drugs. A judge in February refused to certify a class in the case. Lilly says the plaintiffs' claims lacked merit.
Reuters · 1d ago
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
Recent trial data from Viking Therapeutics could make it a potential acquisition target for Pfizer. The GLP-1 weight loss market is projected to grow to $100 billion by 2030. Novo Nordisk and Eli Lilly are the leaders in the space. Pfizer makes logical sense in a potential deal for Viking. The company recently completed a successful Phase 2 trial of its drug in the obesity treatment.
Seeking Alpha · 1d ago
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today
Novo Nordisk has outperformed the market over the past 5 years by 27.13% on an annualized basis. The company has an average annual return of 39.15%. If an investor bought $1000 of NVO stock 5 years ago it would be worth $5,184.96 today.
Benzinga · 1d ago
More
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers Novo Nordisk A/S (ADR) stock information, including NYSE: NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.